Cargando…

Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part II: Cell and Tissue Engineering Therapies

Age-related Macular Degeneration (AMD) is an up-to-date untreatable chronic neurodegenerative eye disease of multifactorial origin, and the main causes of blindness in over 65 y.o. people. It is characterized by a slow progression and the presence of a multitude of factors, highlighting those relate...

Descripción completa

Detalles Bibliográficos
Autores principales: Jemni-Damer, Nahla, Guedan-Duran, Atocha, Fuentes-Andion, María, Serrano-Bengoechea, Nora, Alfageme-Lopez, Nuria, Armada-Maresca, Félix, Guinea, Gustavo V., Perez-Rigueiro, José, Rojo, Francisco, Gonzalez-Nieto, Daniel, Kaplan, David L., Panetsos, Fivos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758210/
https://www.ncbi.nlm.nih.gov/pubmed/33363125
http://dx.doi.org/10.3389/fbioe.2020.588014
_version_ 1783626890547822592
author Jemni-Damer, Nahla
Guedan-Duran, Atocha
Fuentes-Andion, María
Serrano-Bengoechea, Nora
Alfageme-Lopez, Nuria
Armada-Maresca, Félix
Guinea, Gustavo V.
Perez-Rigueiro, José
Rojo, Francisco
Gonzalez-Nieto, Daniel
Kaplan, David L.
Panetsos, Fivos
author_facet Jemni-Damer, Nahla
Guedan-Duran, Atocha
Fuentes-Andion, María
Serrano-Bengoechea, Nora
Alfageme-Lopez, Nuria
Armada-Maresca, Félix
Guinea, Gustavo V.
Perez-Rigueiro, José
Rojo, Francisco
Gonzalez-Nieto, Daniel
Kaplan, David L.
Panetsos, Fivos
author_sort Jemni-Damer, Nahla
collection PubMed
description Age-related Macular Degeneration (AMD) is an up-to-date untreatable chronic neurodegenerative eye disease of multifactorial origin, and the main causes of blindness in over 65 y.o. people. It is characterized by a slow progression and the presence of a multitude of factors, highlighting those related to diet, genetic heritage and environmental conditions, present throughout each of the stages of the illness. Current therapeutic approaches, mainly consisting on intraocular drug delivery, are only used for symptoms relief and/or to decelerate the progression of the disease. Furthermore, they are overly simplistic and ignore the complexity of the disease and the enormous differences in the symptomatology between patients. Due to the wide impact of the AMD and the up-to-date absence of clinical solutions, Due to the wide impact of the AMD and the up-to-date absence of clinical solutions, different treatment options have to be considered. Cell therapy is a very promising alternative to drug-based approaches for AMD treatment. Cells delivered to the affected tissue as a suspension have shown poor retention and low survival rate. A solution to these inconveniences has been the encapsulation of these cells on biomaterials, which contrive to their protection, gives them support, and favor their retention of the desired area. We offer a two-papers critical review of the available and under development AMD therapeutic approaches, from a biomaterials and biotechnological point of view. We highlight benefits and limitations and we forecast forthcoming alternatives based on novel biomaterials and biotechnology methods. In this second part we review the preclinical and clinical cell-replacement approaches aiming at the development of efficient AMD-therapies, the employed cell types, as well as the cell-encapsulation and cell-implant systems. We discuss their advantages and disadvantages and how they could improve the survival and integration of the implanted cells.
format Online
Article
Text
id pubmed-7758210
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77582102020-12-25 Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part II: Cell and Tissue Engineering Therapies Jemni-Damer, Nahla Guedan-Duran, Atocha Fuentes-Andion, María Serrano-Bengoechea, Nora Alfageme-Lopez, Nuria Armada-Maresca, Félix Guinea, Gustavo V. Perez-Rigueiro, José Rojo, Francisco Gonzalez-Nieto, Daniel Kaplan, David L. Panetsos, Fivos Front Bioeng Biotechnol Bioengineering and Biotechnology Age-related Macular Degeneration (AMD) is an up-to-date untreatable chronic neurodegenerative eye disease of multifactorial origin, and the main causes of blindness in over 65 y.o. people. It is characterized by a slow progression and the presence of a multitude of factors, highlighting those related to diet, genetic heritage and environmental conditions, present throughout each of the stages of the illness. Current therapeutic approaches, mainly consisting on intraocular drug delivery, are only used for symptoms relief and/or to decelerate the progression of the disease. Furthermore, they are overly simplistic and ignore the complexity of the disease and the enormous differences in the symptomatology between patients. Due to the wide impact of the AMD and the up-to-date absence of clinical solutions, Due to the wide impact of the AMD and the up-to-date absence of clinical solutions, different treatment options have to be considered. Cell therapy is a very promising alternative to drug-based approaches for AMD treatment. Cells delivered to the affected tissue as a suspension have shown poor retention and low survival rate. A solution to these inconveniences has been the encapsulation of these cells on biomaterials, which contrive to their protection, gives them support, and favor their retention of the desired area. We offer a two-papers critical review of the available and under development AMD therapeutic approaches, from a biomaterials and biotechnological point of view. We highlight benefits and limitations and we forecast forthcoming alternatives based on novel biomaterials and biotechnology methods. In this second part we review the preclinical and clinical cell-replacement approaches aiming at the development of efficient AMD-therapies, the employed cell types, as well as the cell-encapsulation and cell-implant systems. We discuss their advantages and disadvantages and how they could improve the survival and integration of the implanted cells. Frontiers Media S.A. 2020-12-10 /pmc/articles/PMC7758210/ /pubmed/33363125 http://dx.doi.org/10.3389/fbioe.2020.588014 Text en Copyright © 2020 Jemni-Damer, Guedan-Duran, Fuentes-Andion, Serrano-Bengoechea, Alfageme-Lopez, Armada-Maresca, Guinea, Perez-Rigueiro, Rojo, Gonzalez-Nieto, Kaplan and Panetsos. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Jemni-Damer, Nahla
Guedan-Duran, Atocha
Fuentes-Andion, María
Serrano-Bengoechea, Nora
Alfageme-Lopez, Nuria
Armada-Maresca, Félix
Guinea, Gustavo V.
Perez-Rigueiro, José
Rojo, Francisco
Gonzalez-Nieto, Daniel
Kaplan, David L.
Panetsos, Fivos
Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part II: Cell and Tissue Engineering Therapies
title Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part II: Cell and Tissue Engineering Therapies
title_full Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part II: Cell and Tissue Engineering Therapies
title_fullStr Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part II: Cell and Tissue Engineering Therapies
title_full_unstemmed Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part II: Cell and Tissue Engineering Therapies
title_short Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part II: Cell and Tissue Engineering Therapies
title_sort biotechnology and biomaterial-based therapeutic strategies for age-related macular degeneration. part ii: cell and tissue engineering therapies
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758210/
https://www.ncbi.nlm.nih.gov/pubmed/33363125
http://dx.doi.org/10.3389/fbioe.2020.588014
work_keys_str_mv AT jemnidamernahla biotechnologyandbiomaterialbasedtherapeuticstrategiesforagerelatedmaculardegenerationpartiicellandtissueengineeringtherapies
AT guedanduranatocha biotechnologyandbiomaterialbasedtherapeuticstrategiesforagerelatedmaculardegenerationpartiicellandtissueengineeringtherapies
AT fuentesandionmaria biotechnologyandbiomaterialbasedtherapeuticstrategiesforagerelatedmaculardegenerationpartiicellandtissueengineeringtherapies
AT serranobengoecheanora biotechnologyandbiomaterialbasedtherapeuticstrategiesforagerelatedmaculardegenerationpartiicellandtissueengineeringtherapies
AT alfagemelopeznuria biotechnologyandbiomaterialbasedtherapeuticstrategiesforagerelatedmaculardegenerationpartiicellandtissueengineeringtherapies
AT armadamarescafelix biotechnologyandbiomaterialbasedtherapeuticstrategiesforagerelatedmaculardegenerationpartiicellandtissueengineeringtherapies
AT guineagustavov biotechnologyandbiomaterialbasedtherapeuticstrategiesforagerelatedmaculardegenerationpartiicellandtissueengineeringtherapies
AT perezrigueirojose biotechnologyandbiomaterialbasedtherapeuticstrategiesforagerelatedmaculardegenerationpartiicellandtissueengineeringtherapies
AT rojofrancisco biotechnologyandbiomaterialbasedtherapeuticstrategiesforagerelatedmaculardegenerationpartiicellandtissueengineeringtherapies
AT gonzaleznietodaniel biotechnologyandbiomaterialbasedtherapeuticstrategiesforagerelatedmaculardegenerationpartiicellandtissueengineeringtherapies
AT kaplandavidl biotechnologyandbiomaterialbasedtherapeuticstrategiesforagerelatedmaculardegenerationpartiicellandtissueengineeringtherapies
AT panetsosfivos biotechnologyandbiomaterialbasedtherapeuticstrategiesforagerelatedmaculardegenerationpartiicellandtissueengineeringtherapies